bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 6 from Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer
Authors: Abdel-Fatah Tarek M. , Ball Graham , Lee Andrew H.S. , Pinder Sarah , MacMilan R. Douglas , Cornford Eleanor , Moseley Paul M. , Silverman Rafael , Price James , Latham Bruce , Palmer David , Chan Arlene , Ellis Ian O. , Chan Stephen Y.T.
Published: April 2023

Supplementary Figure 6. Receiver operating characteristic (ROC) analysis of Nottingham clinico-pathological response index (NPRI) score and other clinico-pathological covariates were performed for predicting disease free survival in the training (A), internal validation (B), external validation (C) and combined three cohorts (D).
Supplementary Figure 5 from Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer
Authors: Abdel-Fatah Tarek M. , Ball Graham , Lee Andrew H.S. , Pinder Sarah , MacMilan R. Douglas , Cornford Eleanor , Moseley Paul M. , Silverman Rafael , Price James , Latham Bruce , Palmer David , Chan Arlene , Ellis Ian O. , Chan Stephen Y.T.
Published: April 2023

Supplementary Figure 5. Kaplan Meier curves and lifetime table showing disease free survival (DFS) in the training (A), internal validation (B), and external validation (C) cohorts stratified according to Nottingham clinicopathological response index prognostic groups (NPRI-PGs).
Supplementary Figure 3 from Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer
Authors: Abdel-Fatah Tarek M. , Ball Graham , Lee Andrew H.S. , Pinder Sarah , MacMilan R. Douglas , Cornford Eleanor , Moseley Paul M. , Silverman Rafael , Price James , Latham Bruce , Palmer David , Chan Arlene , Ellis Ian O. , Chan Stephen Y.T.
Published: April 2023

Supplementary Figure 3. Multivariable Cox proportional hazards regression analyses for disease free survival (DFS; left panel) and corresponding forest plots (Right panel).
Supplementary Figure 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Authors: Pham Christina D. , Flores Catherine , Yang Changlin , Pinheiro Elaine M. , Yearley Jennifer H. , Sayour Elias J. , Pei Yanxin , Moore Colin , McLendon Roger E. , Huang Jianping , Sampson John H. , Wechsler-Reya Robert , Mitchell Duane A.
Published: April 2023

Orthotopic transplantation maintains histological and subtype specific markers. (A) Hierarchical clustering of subtype specific genes expressed in explanted Ptch1 MB and NSC MB tumors from immunocompetent C57BL/6 hosts. (B) Transplanted Ptch1 MB and NSC MB tumors maintained histological hallmarks of original tumors and were stained with antibodies against synaptophysin (a marker historically used for MB), secreted frizzled-related protein (SFRP1, a marker for SHH tumors) and natriuretic peptide receptor C (NPR3, a marker for Group 3 tumors). Scale bars = 20 µm
Supplementary Table S3 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
Authors: Herman Sarah E.M. , Mustafa Rashida Z. , Jones Jade , Wong Deanna H. , Farooqui Mohammed , Wiestner Adrian
Published: April 2023

Supplementary Table S3: Baseline expression of key chemokine and adhesion molecules
Supplementary Table S2 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
Authors: Herman Sarah E.M. , Mustafa Rashida Z. , Jones Jade , Wong Deanna H. , Farooqui Mohammed , Wiestner Adrian
Published: April 2023

Supplementary Table S2: Patient Characteristics
Supplementary Figure S3 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
Authors: Herman Sarah E.M. , Mustafa Rashida Z. , Jones Jade , Wong Deanna H. , Farooqui Mohammed , Wiestner Adrian
Published: April 2023

Supplementary Figure S3: Effect of in vitro or in vivo ibrutinib treatment on adhesion to stromal cells.
Supplementary Figure S2 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
Authors: Herman Sarah E.M. , Mustafa Rashida Z. , Jones Jade , Wong Deanna H. , Farooqui Mohammed , Wiestner Adrian
Published: April 2023

Supplementary Figure S2: Effect of in vitro ibrutinib treatment on adhesion to fibronectin.
Supplemental Figure Legend from Inhibition of NANOG/NANOGP8 Downregulates MCL-1 in Colorectal Cancer Cells and Enhances the Therapeutic Efficacy of BH3 Mimetics
Authors: Mattoo Abid R. , Zhang Jingyu , Espinoza Luis A. , Jessup J. Milburn
Published: April 2023

Supplemental Figure Legend from Inhibition of NANOG/NANOGP8 Downregulates MCL-1 in Colorectal Cancer Cells and Enhances the Therapeutic Efficacy of BH3 Mimetics
Supplementary Methods S1-2 from Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer
Authors: Lee Se-Ra , Roh Yun-Gil , Kim Seon-Kyu , Lee Ju-Seog , Seol So-Young , Lee Hyun-Hee , Kim Won-Tae , Kim Wun-Jae , Heo Jeonghoon , Cha Hee-Jae , Kang Tae-Hong , Chung Jin Woong , Chu In-Sun , Leem Sun-Hee
Published: April 2023

Supplementary Methods S1-S2. Supplementary Methods S1. Analysis of Microarray gene expression profiling. Supplementary Methods S2. Primer sequences for RT-PCR, real-time PCR and chromatin immunoprecipitation (ChIP) assay.
Supporting Information from Multimodal Image-Guided Surgical and Photodynamic Interventions in Head and Neck Cancer: From Primary Tumor to Metastatic Drainage
Authors: Muhanna Nidal , Cui Liyang , Chan Harley , Burgess Laura , Jin Cheng S. , MacDonald Thomas D. , Huynh Elizabeth , Wang Fan , Chen Juan , Irish Jonathan C. , Zheng Gang
Published: April 2023

Figure S1. The PET/CT imaging of rabbit at 24 h post-intravenous injection of 64Cu-PLP. Figure S2. Representative H&E, pan-Cytokeratin staining and fluorescence microscopic imaging of the tumor (a) and metastatic lymph node (b) after 24 h intravenous injection of 64Cu- PLP Figure S3. The non-toxicity of PLP-PDT to healthy tissues. Figure S4. The temperature change of tumors during laser irradiation. Figure S5. The tumor size change of laser control and PLP control was monitored by CT imaging after treatment. Figure S6. Representative CT images of the regional lymph node post treatment.
Supplementary Figure 2 from Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models
Authors: Francis David M. , Huang Shyhmin , Armstrong Eric A. , Werner Lauryn R. , Hullett Craig , Li Chunrong , Morris Zachary S. , Swick Adam D. , Kragh Michael , Lantto Johan , Kimple Randall J. , Harari Paul M.
Published: April 2023

Additional effect of Pan-HER radiation on DNA damage repair
Supplementary Figure 1 from Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models
Authors: Francis David M. , Huang Shyhmin , Armstrong Eric A. , Werner Lauryn R. , Hullett Craig , Li Chunrong , Morris Zachary S. , Swick Adam D. , Kragh Michael , Lantto Johan , Kimple Randall J. , Harari Paul M.
Published: April 2023

Baseline HER protein levels and effect of Pan-HER on cetuximab-resistant cells
Supplemental Table 1 (Patient Demographics); Supplemental Table 2 (Association of ORR with Rash and Vitiligo) from Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Authors: Freeman-Keller Morganna , Kim Youngchul , Cronin Heather , Richards Allison , Gibney Geoffrey , Weber Jeffrey S.
Published: April 2023

Supplemental Table 1: Detailed patient characteristics of each cohort, including age, gender, race, disease stage, whether CNS disease was present, and what dose of nivolumab and/or vaccine was allocated. Supplemental Table 2: The relationship of overall response rate (ORR, PR + CR vs SD + PD) to vitiligo and rash. The authors found a statistically significant relationship between ORR and rash (p=0.03) and vitiligo (p=0.009).
Supplemental Video 2 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
Authors: van der Sluis Tetje C. , van Duikeren Suzanne , Huppelschoten Suzanna , Jordanova Ekaterina S. , Beyranvand Nejad Elham , Sloots Arjen , Boon Louis , Smit Vincent T.H.B.M. , Welters Marij J.P. , Ossendorp Ferry , van de Water Bob , Arens Ramon , van der Burg Sjoerd H. , Melief Cornelis J.M.
Published: April 2023

Supplemental Video 2. TC-1 cells were in vitro cultured and treated with cisplatin (2 ÃŽÂ¼g/ml). Cell death was followed for 22 hours using Annexin-V staining and automated imaging on a BD pathway 855 imager. Every hour a picture was taken.
Supplementary Table Set S36-S39 from Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Authors: Burstein Matthew D. , Tsimelzon Anna , Poage Graham M. , Covington Kyle R. , Contreras Alejandro , Fuqua Suzanne A.W. , Savage Michelle I , Osborne C. Kent , Hilsenbeck Susan G. , Chang Jenny C. , Mills Gordon B. , Lau Ching C. , Brown Powel H.
Published: April 2023

Table S36. Differentially Expressed Genes (>2 fold) Present in Pathways, Regulator Networks, or DNA-Correlated in Subtype 1 (LAR). Table S37. Differentially Expressed Genes (>2 fold) Present in Pathways, Regulator Networks, or DNA-Correlated in Subtype 2 (MES). Table S38. Differentially Expressed Genes (>2 fold) Present in Pathways, Regulator Networks, or DNA-Correlated in Subtype 3 (BLIS). Table S39. Differentially Expressed Genes (>2 fold) Present in Pathways, Regulator Networks, or DNA-Correlated in Subtype 4 (BLIA).
Supplementary Table Set S25-S29 from Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Authors: Burstein Matthew D. , Tsimelzon Anna , Poage Graham M. , Covington Kyle R. , Contreras Alejandro , Fuqua Suzanne A.W. , Savage Michelle I , Osborne C. Kent , Hilsenbeck Susan G. , Chang Jenny C. , Mills Gordon B. , Lau Ching C. , Brown Powel H.
Published: April 2023

Table S25. Subtype 1 (LAR) Pathways with Differentially Expressed Members in Either the Discovery, Validation, or External Sets Table S26. Subtype 2 (MES) Pathways with Differentially Expressed Members in Either the Discovery, Validation, or External Sets Table S27. Subtype 3 (BLIS) Pathways with Differentially Expressed Members in Either the Discovery, Validation, or External Sets Table S28. Subtype 4 (BLIA) Pathways with Differentially Expressed Members in Either the Discovery, Validation, or External Sets Table S29. Pathway Overlap Between Sets by Subtypes.
Supplementary Table Set S19-S22 from Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Authors: Burstein Matthew D. , Tsimelzon Anna , Poage Graham M. , Covington Kyle R. , Contreras Alejandro , Fuqua Suzanne A.W. , Savage Michelle I , Osborne C. Kent , Hilsenbeck Susan G. , Chang Jenny C. , Mills Gordon B. , Lau Ching C. , Brown Powel H.
Published: April 2023

Table S19. Assignment of Curtis Set Clusters by Discovery Set Centroids. Table S20. Assignment of Sabatier Set Clusters by Discovery Set Centroids. Table S21. Summary of Subtype Assignment by Data Set. Table S22. Comparison of Subtype Assignment of Public Data Versus Study Sets
Supplemental Table 1 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
Authors: Bikos Vasilis , Karypidou Maria , Stalika Evangelia , Baliakas Panagiotis , Xochelli Aliki , Sutton Lesley-Ann , Papadopoulos George , Agathangelidis Andreas , Papadopoulou Evdoxia , Davis Zadie , Algara Patricia , Kanellis George , Traverse-Glehen Alexandra , Mollejo Manuela , Anagnostopoulos Achilles , Ponzoni Maurilio , Gonzalez David , Pospisilova Sarka , Matutes Estella , Piris Miguel Angel , Papadaki Theodora , Ghia Paolo , Rosenquist Richard , Oscier David , Darzentas Nikos , Tzovaras Dimitrios , Belessi Chrysoula , Hadzidimitriou Anastasia , Stamatopoulos Kostas
Published: April 2023

Analyzed IGH, IGK/L rearrangements. Annotation characteristics
Supplementary Figure S1-S9 from Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Authors: Burstein Matthew D. , Tsimelzon Anna , Poage Graham M. , Covington Kyle R. , Contreras Alejandro , Fuqua Suzanne A.W. , Savage Michelle I , Osborne C. Kent , Hilsenbeck Susan G. , Chang Jenny C. , Mills Gordon B. , Lau Ching C. , Brown Powel H.
Published: April 2023

Figure S1. Full clustering metrics in support of a 4 cluster model in the discovery set with membership as defined by TNBCType. Figure S2. Full clustering metrics in support of a 4 cluster model in the validation set with membership as defined by the TNBCType tool Figure S3. Allred scores for clinical IHC of ER, PR, and Her2 protein expression for samples in the discovery and validation sets. Figure S4. Gene expression for discovery and validation sets by NMF Figure S5. NMF of both datasets (discovery and validation, renormalized together) of study data using feature set of 2188 genes utilized in Lehmann et al. (2010) and comparison of resulting clusters t Figure S6. ESR1 expression for ER-positive breast cancers, LAR TNBCs, and all other TNBCs. Figure S7. Expression of common differentially expressed genes in claudin-low tumors selected for their role in luminal differentiation from Prat et al. (2010). Figure S8. Aberrant fraction and ploidy of ASCAT derived copy number estimates. Figure S9. ASCAT derived copy number events reveals distinctive gains and losses that segregate LAR subtype tumors from remaining subtypes.
Supplementary Figure 1 from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Authors: Kobayashi Yoshihisa , Togashi Yosuke , Yatabe Yasushi , Mizuuchi Hiroshi , Jangchul Park , Kondo Chiaki , Shimoji Masaki , Sato Katsuaki , Suda Kenichi , Tomizawa Kenji , Takemoto Toshiki , Hida Toyoaki , Nishio Kazuto , Mitsudomi Tetsuya
Published: April 2023

Supplementary Figure 1. Western blot analyses for phospho-HER2.
Supplementary Table S1: Combination therapies in clinical trials involving immune checkpoint inhibitors from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Authors: Gide Tuba N. , Wilmott James S. , Scolyer Richard A. , Long Georgina V.
Published: April 2023

Supplementary Table S1 summarizes clinical trials of combinatorial therapies that include immune checkpoint inhibitors. This includes combined immune checkpoint blockade, as well as the combination of immune checkpoint inhibitors with radiotherapy, and epigenetic modulators.
Supplementary Tables from A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma
Authors: Gómez Soledad , Garrido-Garcia Alícia , Garcia-Gerique Laura , Lemos Isadora , Suñol Mariona , de Torres Carmen , Kulis Marta , Pérez-Jaume Sara , Carcaboso Ángel M. , Luu Betty , Kieran Mark W. , Jabado Nada , Kozlenkov Alexey , Dracheva Stella , Ramaswamy Vijay , Hovestadt Volker , Johann Pascal , Jones David T.W. , Pfister Stefan M. , Morales La Madrid Andrés , Cruz Ofelia , Taylor Michael D. , Martin-Subero Jose-Ignacio , Mora Jaume , Lavarino Cinzia
Published: April 2023

Supplementary Table 1 SampleSheet Supplementary Table 2 GEO_IDs Supplementary Table 3 EpiWNT-SHH_data Supplementary Table 4 EpiWNT-SHH_test Supplementary Table 5 EpiG3-G4_data Supplementary Table 6 EpiG3-G4_test
Supplemental Figure Legend from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ
Authors: Soong Ruey-Shyang , Song Liwen , Trieu Janson , Knoff Jayne , He Liangmei , Tsai Ya-Chea , Huh Warner , Chang Yung-Nien , Cheng Wen-Fang , Roden Richard B.S. , Wu T.-C. , Trimble Cornelia L. , Hung Chien-Fu
Published: April 2023

Supplemental Figure Legend
Supplementary Video 1 from Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
Authors: Wen Yunfei , Graybill Whitney S. , Previs Rebecca A. , Hu Wei , Ivan Cristina , Mangala Lingegowda S. , Zand Behrouz , Nick Alpa M. , Jennings Nicholas B. , Dalton Heather J. , Sehgal Vasudha , Ram Prahlad , Lee Ju-Seog , Vivas-Mejia Pablo E. , Coleman Robert L. , Sood Anil K.
Published: April 2023

Supplementary Video 1. 3-D SKOV3ip1 spheroids expressing pGFP-RFP-LC3 were treated with control IgG
Supplemental Table 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Authors: Doñate Fernando , Raitano Arthur , Morrison Kendall , An Zili , Capo Linnette , Aviña Hector , Karki Sher , Morrison Karen , Yang Peng , Ou Jimmy , Moriya Ryuichi , Shostak Yuriy , Malik Faisal , Nadell Rossana , Liu Wendy , Satpayev Daulet , Atkinson John , Joseph Ingrid B.J. , Pereira Daniel S. , Challita-Eid Pia M. , Stover David R.
Published: April 2023

Supplemental Table 1. Quantification of ENPP3 Expression in Various Carcinomas
Supplementary Table 3-8 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Authors: Malouf Gabriel G. , Su Xiaoping , Zhang Jianping , Creighton Chad J. , Ho Thai H. , Lu Yue , Raynal Noël J.-M. , Karam Jose A. , Tamboli Pheroze , Allanick Frederick , Mouawad Roger , Spano Jean-Philippe , Khayat David , Wood Christopher G. , Jelinek Jaroslav , Tannir Nizar M.
Published: April 2023

Supplementary Table 3: Ingenuity Pathway Analysis (IPA) for genes which gain promoter DNA methylation in C1 relative to C2 epi-cluster. Supplementary Table 4: Gene Ontology analysis for differentially methylated regions (DMR) between C1 and C2 epi-clusters, as assessed by GREAT online tool. Supplementary Table 5: List of motifs enriched in differentially methylated regions between C1 and C2 epi-clusters, as assessed by GREAT online tool. Supplementary Table 6: DAVID functional annotations analysis for enriched pathways related to genes which gain DNA methylation in renal cell carcinoma samples. Supplementary Table 7: List of gene promoters located in CG islands and which are assessed for DNA methylation using DREAM. The genes which showed the highest frequency of DNA methylation in our dataset are in the top. Furthermore, the frequency of gene promoters which gain DNA methylation in either RCC samples derived from the proximal or distal cells of the nephron are also reported. Supplementary Table 8: Validation dataset showing the prevalence of promoter DNA methylation for 25 genes in clear-cell renal cell carcinoma dataset of The Cancer Genome Atlas (TCGA) project. Those genes were both methylated and repressed in the TCGA dataset.
Supplemental Methods from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Authors: Doñate Fernando , Raitano Arthur , Morrison Kendall , An Zili , Capo Linnette , Aviña Hector , Karki Sher , Morrison Karen , Yang Peng , Ou Jimmy , Moriya Ryuichi , Shostak Yuriy , Malik Faisal , Nadell Rossana , Liu Wendy , Satpayev Daulet , Atkinson John , Joseph Ingrid B.J. , Pereira Daniel S. , Challita-Eid Pia M. , Stover David R.
Published: April 2023

Supplemental Methods
Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Authors: Doñate Fernando , Raitano Arthur , Morrison Kendall , An Zili , Capo Linnette , Aviña Hector , Karki Sher , Morrison Karen , Yang Peng , Ou Jimmy , Moriya Ryuichi , Shostak Yuriy , Malik Faisal , Nadell Rossana , Liu Wendy , Satpayev Daulet , Atkinson John , Joseph Ingrid B.J. , Pereira Daniel S. , Challita-Eid Pia M. , Stover David R.
Published: April 2023

Supplemental Figure 5. Immunostaining for cleaved PARP-1 and PPH3 in tumors.
Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Authors: Doñate Fernando , Raitano Arthur , Morrison Kendall , An Zili , Capo Linnette , Aviña Hector , Karki Sher , Morrison Karen , Yang Peng , Ou Jimmy , Moriya Ryuichi , Shostak Yuriy , Malik Faisal , Nadell Rossana , Liu Wendy , Satpayev Daulet , Atkinson John , Joseph Ingrid B.J. , Pereira Daniel S. , Challita-Eid Pia M. , Stover David R.
Published: April 2023

Supplemental Figure 2. AGS16-7.8 does not inhibit the enzymatic activity of purified ENPP3.
Supplementary Figures from Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti–Prostate Cancer Activity
Authors: Wang Xiaodong , Huang Ying , Christie Amanda , Bowden Michaela , Lee Gwo-Shu Mary , Kantoff Philip W. , Sweeney Christopher J.
Published: April 2023

Fig. S1. Cabozantinib enhances the inhibitory activities of abiraterone for prostate cancer growth in prostate cancer cell lines and in xenograft mouse model. Fig. S2. Detection of tyrosine-phosphorylated receptors in LAPC4-CR, VCaP and PC3 cells by the Human Phospho-Receptor Tyrosine Kinase Array. Fig. S3. Assessment of p-cMet and p-IGF-1R levels in residual resistant xenograft tumors after prolonged in vivo treatment Fig. S4. Various prostate cancer cell lines (LAPC4, LAPC4-CR and VCaP) were treated with different concentrations of cMet inhibitor (crizotinib), VEGFR2 inhibitor (suntinib) and IGF-1R inhibitor (NVP-AEW541).
Supplemental Figure 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Authors: Doñate Fernando , Raitano Arthur , Morrison Kendall , An Zili , Capo Linnette , Aviña Hector , Karki Sher , Morrison Karen , Yang Peng , Ou Jimmy , Moriya Ryuichi , Shostak Yuriy , Malik Faisal , Nadell Rossana , Liu Wendy , Satpayev Daulet , Atkinson John , Joseph Ingrid B.J. , Pereira Daniel S. , Challita-Eid Pia M. , Stover David R.
Published: April 2023

Supplemental Figure 1. AGS16-7.8 and AGS16F do not bind to ENPP1 or ENPP2 proteins.
Supplementary Figures 1 - 4, Tables 1 - 2 from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
Authors: Meetze Kristan , Vincent Sylvie , Tyler Steven , Mazsa Elizabeth K. , Delpero Andrea R. , Bottega Steve , McIntosh Donna , Nicoletti Richard , Winston William M. , Weiler Solly , Feng Bin , Gyuris Jeno , Weng Zhigang
Published: April 2023

Supplementary Table 1. The contingency table for the Fisherâ€™s exact test for xenograft models used in the study. Supplementary Table 2. NRG1 and ERBB3 expression in human cancers from TCGA database. Supplementary Figure 1. Effect of AV-203 on xenograft models in vivo. Supplementary Figure 2. Analysis of NRG1 expression by immunohistochemistry. Supplementary Figure 3. Evaluation of NRG1 and ERBB3 expression in human cancers using TCGA database. Supplementary Figure 4. Correlation analysis between efficacy of AV-203 and the expression levels of ERBB3 (A) or NRG1 (B) in 32 human cancer xenografts included in the study.
Supplementary Table and Figure Legend from DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia
Authors: Sehgal Alison R. , Gimotty Phyllis A. , Zhao Jianhua , Hsu Jing-Mei , Daber Robert , Morrissette Jennifer D. , Luger Selina , Loren Alison W. , Carroll Martin
Published: April 2023

Supplementary Table and Figure Legend
Supplemental Figure S2 from DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia
Authors: Sehgal Alison R. , Gimotty Phyllis A. , Zhao Jianhua , Hsu Jing-Mei , Daber Robert , Morrissette Jennifer D. , Luger Selina , Loren Alison W. , Carroll Martin
Published: April 2023

Supplemental Figure S2. Circos diagram of concurrent mutations in the 152 patient cohort
Supplementary Methods, Figures 1 - 4, Table 1 from Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Authors: Taube Janis M. , Klein Alison , Brahmer Julie R. , Xu Haiying , Pan Xiaoyu , Kim Jung H. , Chen Lieping , Pardoll Drew M. , Topalian Suzanne L. , Anders Robert A.
Published: April 2023

PDF file - 685KB, Supplementary Figure 1 showing a photomicrograph of intratumoral lymphoid aggregates. Supplementary Figure 2 showing the association of PD-L1 expression with immune infiltrates. Supplementary Figure 3 showing the PD-L1 and PD-1 expression by the immune infiltrates in colorectal carcinoma. Supplementary Figure 4 showing the immunoarchitecture of a melanoma lymph node metastasis. Supplementary Table 1 showing the relationship between pre-treatment microenviornmental parameters in the tumor specimen demonstrating the highest expression of each variable across all specimens from a single patient and the clinical response to anti-PD-1.
Supplemental Table 3. from NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem–Like Cells in Adenoid Cystic Carcinoma
Authors: Panaccione Alex , Chang Michael T. , Carbone Beatrice E. , Guo Yan , Moskaluk Christopher A. , Virk Renu K. , Chiriboga Luis , Prasad Manju L. , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Ivanov Sergey V.
Published: April 2023

Suppressive effects of FABP7 depletion on gene expression in Accx11 cells.
Supplemental Table 1. from NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem–Like Cells in Adenoid Cystic Carcinoma
Authors: Panaccione Alex , Chang Michael T. , Carbone Beatrice E. , Guo Yan , Moskaluk Christopher A. , Virk Renu K. , Chiriboga Luis , Prasad Manju L. , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Ivanov Sergey V.
Published: April 2023

Validation of ACC cell cultures via microsatellite analysis.
Supplementary Figure 1 from Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations
Authors: Bucheit Amanda D. , Chen Guo , Siroy Alan , Tetzlaff Michael , Broaddus Russell , Milton Denai , Fox Patricia , Bassett Roland , Hwu Patrick , Gershenwald Jeffrey E. , Lazar Alexander J. , Davies Michael A.
Published: April 2023

Supplementary Figure 1. Representative images of PTEN IHC results in FFPE melanoma tissue samples.
Figure S2 from Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations
Authors: Bucheit Amanda D. , Chen Guo , Siroy Alan , Tetzlaff Michael , Broaddus Russell , Milton Denai , Fox Patricia , Bassett Roland , Hwu Patrick , Gershenwald Jeffrey E. , Lazar Alexander J. , Davies Michael A.
Published: April 2023

Figure S2. Flow of samples
Supplemental Figure 1. from NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem–Like Cells in Adenoid Cystic Carcinoma
Authors: Panaccione Alex , Chang Michael T. , Carbone Beatrice E. , Guo Yan , Moskaluk Christopher A. , Virk Renu K. , Chiriboga Luis , Prasad Manju L. , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Ivanov Sergey V.
Published: April 2023

Expression of SOX10, NOTCH1, FABP7, and CD133 in ACC tumor specimens from patients (P) and PDX (X). The comparison is based on previously produced Affymetrix data (6).
Supplemental Tables S1-S4 from ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy
Authors: Chen Zheng , Teo Albert E. , McCarty Nami
Published: April 2023

Table S1. Jeko, SP53 and Z138 MCL cells (5x103) were cultured in PHA-LCM methylcellulose medium, and the numbers of colonies were counted a week later. SDF-1 (200 ng/ml) or AMD3100 (40 mM) or AMD3100 with SDF-1 were added during culture. Table S2. MCL cells (5x103) were cultured in PHA-LCM medium with human bone marrow stromal cells, HS27a, or SDF-1 neutralizing antibodies (100 mg/ml). In some experiments, MCL cells were also cultured using stromal cells for 24 hours and collected for the colony forming assays. Table S3. Decreased quiescent PKH-positive cell recovery in vivo upon CXCR4 silencing. GFP-positive CXCR4 shRNA MCL or control shRNA cells (5x105) were labeled using the fluorescent dye PKH26 and injected into NOD/SCID mice to evaluate engraftment. Mice were sacrificed after 48 hours, and the cells were isolated from the osteoblastic and vascular niches of the bone marrow and spleens. Table S4. Decreased quiescent PKH-positive cell recovery in vivo upon Beclin1 silencing. GFP-positive Beclin1 shRNA MCL or control shRNA cells were labeled using the fluorescent dye PKH26 and injected into NOD/SCID mice to evaluate engraftment. Mice were sacrificed after 48 hours, and the cells were isolated from the osteoblastic niche and vascular niches of the bone marrow and spleens.
Supplemental Table Legends S1-S4 from ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy
Authors: Chen Zheng , Teo Albert E. , McCarty Nami
Published: April 2023

Supplemental Table Legends
Supplementary Figure 4 from Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Authors: Dai Min , Yip Yuen Yee , Hellstrom Ingegerd , Hellstrom Karl Erik
Published: April 2023

Expression of surface molecules in TIL of mice receiving mAb combinations.
Supplementary Figure 2 from Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Authors: Dai Min , Yip Yuen Yee , Hellstrom Ingegerd , Hellstrom Karl Erik
Published: April 2023

Expression of surface molecules in TLN and spleen of mice receiving the mAb treatments.
Supplemental Figure 3 from Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling
Authors: Romick-Rosendale Lindsey E. , Hoskins Elizabeth E. , Privette Vinnedge Lisa M. , Foglesong Grant D. , Brusadelli Marion G. , Potter S. Steven , Komurov Kakajan , Brugmann Samantha A. , Lambert Paul F. , Kimple Randall J. , Virts Elizabeth L. , Hanenberg Helmut , Gillison Maura L. , Wells Susanne I.
Published: April 2023

Chick Chorioallantoic Membrane (CAM) assay for UM-SCC1 cells.
Supplemental Figure 2 from Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling
Authors: Romick-Rosendale Lindsey E. , Hoskins Elizabeth E. , Privette Vinnedge Lisa M. , Foglesong Grant D. , Brusadelli Marion G. , Potter S. Steven , Komurov Kakajan , Brugmann Samantha A. , Lambert Paul F. , Kimple Randall J. , Virts Elizabeth L. , Hanenberg Helmut , Gillison Maura L. , Wells Susanne I.
Published: April 2023

Cell attachment and migration assays for UM-SCC1 cells.
Supplementary Data from A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome
Authors: Schell Michael J. , Yang Mingli , Missiaglia Edoardo , Delorenzi Mauro , Soneson Charlotte , Yue Binglin , Nebozhyn Michael V. , Loboda Andrey , Bloom Gregory , Yeatman Timothy J.
Published: April 2023

Supplementary Figures and Tables
Finalized Supplementary Data from PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors
Authors: Croessmann Sarah , Sheehan Jonathan H. , Lee Kyung-min , Sliwoski Gregory , He Jie , Nagy Rebecca , Riddle David , Mayer Ingrid A. , Balko Justin M. , Lanman Richard , Miller Vincent A. , Cantley Lewis C. , Meiler Jens , Arteaga Carlos L.
Published: April 2023

Supp Figure S1-S5 with legends, Supp Tables S1-S4
Supplementary Figure S2 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Authors: Tsai Harrison , Morais Carlos L. , Alshalalfa Mohammed , Tan Hsueh-Li , Haddad Zaid , Hicks Jessica , Gupta Nilesh , Epstein Jonathan I. , Netto George J. , Isaacs William B. , Luo Jun , Mehra Rohit , Vessella Robert L. , Karnes R. Jeffrey , Schaeffer Edward M. , Davicioni Elai , De Marzo Angelo M. , Lotan Tamara L.
Published: April 2023

Supplementary Figure S2: The ratio of CDKN2A/CCND1 is not as tightly correlated with Rb functional and genetic status in publicly available data from castate resistant prostate cancer (CRPC) metastases in rapid autopsy cohort.
Supplementary Table 1 from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Authors: Skarzynski Martin , Niemann Carsten U. , Lee Yuh Shan , Martyr Sabrina , Maric Irina , Salem Dalia , Stetler-Stevenson Maryalice , Marti Gerald E. , Calvo Katherine R. , Yuan Constance , Valdez Janet , Soto Susan , Farooqui Mohammed Z.H. , Herman Sarah E.M. , Wiestner Adrian
Published: April 2023

Supplementary Table 1. Characteristics of all patients studied.
Supplementary Figure 3 from Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Authors: Tucker Douglass W. , Getchell Christopher R. , McCarthy Eric T. , Ohman Anders W. , Sasamoto Naoko , Xu Shuyun , Ko Joo Yeon , Gupta Mamta , Shafrir Amy , Medina Jamie E. , Lee Jonathan J. , MacDonald Lauren A. , Malik Ammara , Hasselblatt Kathleen T , Li Wenjing , Zhang Hong , Kaplan Samuel J. , Murphy George F. , Hirsch Michelle S. , Liu Joyce F. , Matulonis Ursula A. , Terry Kathryn L. , Lian Christine G. , Dinulescu Daniela M.
Published: April 2023

Western blot analysis of A2780, IF quantification, immunoblot quantification in human and murine cell lines
Supplementary Figure 1 from Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Authors: Tucker Douglass W. , Getchell Christopher R. , McCarthy Eric T. , Ohman Anders W. , Sasamoto Naoko , Xu Shuyun , Ko Joo Yeon , Gupta Mamta , Shafrir Amy , Medina Jamie E. , Lee Jonathan J. , MacDonald Lauren A. , Malik Ammara , Hasselblatt Kathleen T , Li Wenjing , Zhang Hong , Kaplan Samuel J. , Murphy George F. , Hirsch Michelle S. , Liu Joyce F. , Matulonis Ursula A. , Terry Kathryn L. , Lian Christine G. , Dinulescu Daniela M.
Published: April 2023

IHC composite scoring system, cohort 5-hmC scoring system compared to normal OSE and FTE
Additional Materials and Methods from Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Authors: Tucker Douglass W. , Getchell Christopher R. , McCarthy Eric T. , Ohman Anders W. , Sasamoto Naoko , Xu Shuyun , Ko Joo Yeon , Gupta Mamta , Shafrir Amy , Medina Jamie E. , Lee Jonathan J. , MacDonald Lauren A. , Malik Ammara , Hasselblatt Kathleen T , Li Wenjing , Zhang Hong , Kaplan Samuel J. , Murphy George F. , Hirsch Michelle S. , Liu Joyce F. , Matulonis Ursula A. , Terry Kathryn L. , Lian Christine G. , Dinulescu Daniela M.
Published: April 2023

Additional Materials and Methods
Supplemental Figures S3-5 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Authors: Boi Michela , Gaudio Eugenio , Bonetti Paola , Kwee Ivo , Bernasconi Elena , Tarantelli Chiara , Rinaldi Andrea , Testoni Monica , Cascione Luciano , Ponzoni Maurilio , Mensah Afua Adjeiwaa , Stathis Anastasios , Stussi Georg , Riveiro María Eugenia , Herait Patrice , Inghirami Giorgio , Cvitkovic Esteban , Zucca Emanuele , Bertoni Francesco
Published: April 2023

Supplemental Figures S3-5. Supplemental Figures S3: the gene expression changes induced by OTX015 in DLBCL cell lines. Supplemental Figures S4: network of genes affected by OTX015. Supplemental Figures S5: similar biologic effects of OTX015 and JQ1.
supplemental figure legends from Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Authors: Guo Yelei , Feng Kaichao , Liu Yang , Wu Zhiqiang , Dai Hanren , Yang Qingming , Wang Yao , Jia Hejin , Han Weidong
Published: April 2023

supplemental figure legends
Supplemental Figure S5 from Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo
Authors: Kimbrough Charles W. , Khanal Anil , Zeiderman Matthew , Khanal Bigya R. , Burton Neal C. , McMasters Kelly M. , Vickers Selwyn M. , Grizzle William E. , McNally Lacey R.
Published: April 2023

Supplemental Figure S5 The movie clip demonstrates spectrally unmixed oxy-hemoglobin (red color, left panel), deoxy-hemoglobin (blue color, middle panel), and V7-750 probe (green color, right panel) which were obtained using MSOT imaging as in Figure 3. Of special note, deoxy-hemoglobin (middle panel) denotes tumor location and corresponds to V7-750 signal (right panel).
Supplemental Figure S4 from Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo
Authors: Kimbrough Charles W. , Khanal Anil , Zeiderman Matthew , Khanal Bigya R. , Burton Neal C. , McMasters Kelly M. , Vickers Selwyn M. , Grizzle William E. , McNally Lacey R.
Published: April 2023

Supplemental Figure S4: (A) S2013 mouse demonstrate localization of V7-750 probe, but not K7-750 to the region of the tumor bed, signal intensity in the pancreas tumor of S2013 mice with injection of V7-750 is 578.3 MSOT a.u., compared to 5.1 for K7-750 with p=0.0005. K7-750 signal was largely localized in the kidney.(B) Orthogonal views of the pancreatic tumor bed at 4 hours demonstrate distribution of V7-750 probe signal throughout the tumor bed at 4 hours, while minimal accumulation is observed with K7-750.
Supplementary Table 1 from A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
Authors: Moreno Lucas , Marshall Lynley V. , Pearson Andrew D.J. , Morland Bruce , Elliott Martin , Campbell-Hewson Quentin , Makin Guy , Halford Sarah E.R. , Acton Gary , Ross Philip , Kazmi-Stokes Shamim , Lock Victoria , Rodriguez Ana , Lyons John F. , Boddy Alan V. , Griffin Melanie J. , Yule Murray , Hargrave Darren
Published: April 2023

Supplementary Table 1. Summary of pharmacodynamic changes observed in paired skin punch biopsies. Skin punch biopsies were optional until a dose limiting toxicity was found (11.5 mg/m2/day) when they were mandated. Inhibition of pHH3 (substrate for Aurora kinase B) can be observed in the majority of patients from the 11.5 mg/m2/day dose level. Decreases in Ki67 can be observed from the 18.5 mg/m2/day dose level.
Supplementary Tables S1-S4 from pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma
Authors: Ruf Melanie , Mittmann Christiane , Nowicka Anna M. , Hartmann Arndt , Hermanns Thomas , Poyet Cédric , van den Broek Maries , Sulser Tullio , Moch Holger , Schraml Peter
Published: April 2023

Supplementary table S1: Antibodies used for Western blot analysis, immunohistochemistry and ChIP. Supplementary table S2: VHL and HIF1α mutation states in cell lines. Supplementary table S3: Primers used for ChIP analysis. Supplementary table S4: Correlations between tumor stage, grade and CD70 in ccRCC.
Supplementary Figure 3 from Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
Authors: Zhang Xin , Yang Xiaoyun , Zhang Yanli , Liu Xinfeng , Zheng Guixi , Yang Yongmei , Wang Lili , Du Lutao , Wang Chuanxin
Published: April 2023

Supplementary Figure 3. ROC curve analyses using cell free Bmi-1 for discriminating adenoma(A) and advanced adenoma(B).
Supplementary Table S1 from Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer
Authors: Lu Donghao , Sinnott Jennifer A. , Valdimarsdóttir Unnur , Fang Fang , Gerke Travis , Tyekucheva Svitlana , Fiorentino Michelangelo , Lambe Mats , Sesso Howard D. , Sweeney Christopher J. , Wilson Kathryn M. , Giovannucci Edward L. , Loda Massimo , Mucci Lorelei A. , Fall Katja
Published: April 2023

List of genes included in the five stress-related signaling pathways
Supplementary Materials from A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
Authors: Puzanov Igor , Lindsay Colin R. , Goff Laura , Sosman Jeff , Gilbert Jill , Berlin Jordan , Poondru Srinivasu , Simantov Ronit , Gedrich Rich , Stephens Andrew , Chan Emily , Evans T.R. Jeffry
Published: April 2023

Supplementary Materials. Table 1. Drug-related adverse events (AEs) occurring during the initial 21 days of dosing in the expansion cohorts Table 2. Plasma OSI-906 pharmacokinetic parameters (expansion cohorts, Days 1 and 22) Table 3. Dose proportionality assessment of OSI-906 across dose levels Figure 2. KRAS mutations status and time on study for patients with colorectal cancer treated with OSI-906 150 mg BID.
Supplementary Fig. 1 from A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
Authors: Puzanov Igor , Lindsay Colin R. , Goff Laura , Sosman Jeff , Gilbert Jill , Berlin Jordan , Poondru Srinivasu , Simantov Ronit , Gedrich Rich , Stephens Andrew , Chan Emily , Evans T.R. Jeffry
Published: April 2023

Supplementary Fig. 1. Patient disposition.
Figure S3 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Authors: Charych Deborah H. , Hoch Ute , Langowski John L. , Lee Steve R. , Addepalli Murali K. , Kirk Peter B. , Sheng Dawei , Liu Xiaofeng , Sims Paul W. , VanderVeen Laurie A. , Ali Cherie F. , Chang Thomas K. , Konakova Marina , Pena Rhoneil L. , Kanhere Rupesh S. , Kirksey Yolanda M. , Ji Chunmei , Wang Yujun , Huang Jicai , Sweeney Theresa D. , Kantak Seema S. , Doberstein Stephen K.
Published: April 2023

Antitumor immunity stimulated by NKTR-214 and anti-CTLA-4 in mouse EMT6 tumors requires innate and adaptive immune responses
Supplementary Figure 4 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Authors: Garcia Jacqueline S. , Huang Min , Medeiros Bruno C. , Mitchell Beverly S.
Published: April 2023

(A) Representative FACS plot of sorted NPMc+ primary leukemic blasts (patient AML6) and (B) mRNA expression by qPCR using the same AML patient samples tested in Figure 4.
Supplementary Table 3 from SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor
Authors: Chiang Cheng-Yao , Pan Chin-Chen , Chang Hong-Yi , Lai Ming-Derg , Tzai Tzong-Shin , Tsai Yuh-Shyan , Ling Pin , Liu Hsiao-Sheng , Lee Bi-Fang , Cheng Hong-Ling , Ho Chung-Liang , Chen Shu-Hui , Chow Nan-Haw
Published: April 2023

Univariate and stepwise multivariate regression analyses for cumulative incidences of progression in patients with bladder urothelial tumors treated by transurethral resection without intravesical instillation.
Supplementary Table 2 from SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor
Authors: Chiang Cheng-Yao , Pan Chin-Chen , Chang Hong-Yi , Lai Ming-Derg , Tzai Tzong-Shin , Tsai Yuh-Shyan , Ling Pin , Liu Hsiao-Sheng , Lee Bi-Fang , Cheng Hong-Ling , Ho Chung-Liang , Chen Shu-Hui , Chow Nan-Haw
Published: April 2023

Protein identification of urine from patients with BPH.
Supplementary Table 1 from SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor
Authors: Chiang Cheng-Yao , Pan Chin-Chen , Chang Hong-Yi , Lai Ming-Derg , Tzai Tzong-Shin , Tsai Yuh-Shyan , Ling Pin , Liu Hsiao-Sheng , Lee Bi-Fang , Cheng Hong-Ling , Ho Chung-Liang , Chen Shu-Hui , Chow Nan-Haw
Published: April 2023

Protein identification of urine from 3 pair of patients with UC.
Supplementary Figure Legend, Supplementary materials and methods from SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor
Authors: Chiang Cheng-Yao , Pan Chin-Chen , Chang Hong-Yi , Lai Ming-Derg , Tzai Tzong-Shin , Tsai Yuh-Shyan , Ling Pin , Liu Hsiao-Sheng , Lee Bi-Fang , Cheng Hong-Ling , Ho Chung-Liang , Chen Shu-Hui , Chow Nan-Haw
Published: April 2023

Supplementary Figure legend, Supplementary materials and methods
Supplemental legend from CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer
Authors: Michaels Alex D. , Newhook Timothy E. , Adair Sara J. , Morioka Sho , Goudreau Bernadette J. , Nagdas Sarbajeet , Mullen Matthew G. , Persily Jesse B. , Bullock Timothy N. J. , Slingluff Craig L. , Ravichandran Kodi S. , Parsons J. Thomas , Bauer Todd W.
Published: April 2023

Supplemental legend
Supplementary Figure 3 from SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor
Authors: Chiang Cheng-Yao , Pan Chin-Chen , Chang Hong-Yi , Lai Ming-Derg , Tzai Tzong-Shin , Tsai Yuh-Shyan , Ling Pin , Liu Hsiao-Sheng , Lee Bi-Fang , Cheng Hong-Ling , Ho Chung-Liang , Chen Shu-Hui , Chow Nan-Haw
Published: April 2023

Co-localization of SH3BGRL3 with EGFR
Supplementary Figure 1 from Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Authors: Gainor Justin F. , Tan Daniel S.W. , De Pas Tomasso , Solomon Benjamin J. , Ahmad Aziah , Lazzari Chiara , de Marinis Filippo , Spitaleri Gianluca , Schultz Katherine , Friboulet Luc , Yeap Beow Y. , Engelman Jeffrey A. , Shaw Alice T.
Published: April 2023

Supplementary Figure 1. Individual swimmer plots for each patient who underwent a post-crizotinib/pre-ceritinib biopsy
Supplementary Figure 2 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Authors: Zegers Catharina M.L. , Rekers Nicolle H. , Quaden Dana H.F. , Lieuwes Natasja G. , Yaromina Ala , Germeraad Wilfred T.V. , Wieten Lotte , Biessen Erik A.L. , Boon Louis , Neri Dario , Troost Esther G.C. , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary Figure 2. FACS gating strategy (tumor)